Summary

Antifungal Treatment Market Research Report Forecast to 2032

Market Overview
The Antifungal Treatment Market is expected to register a CAGR of 3.89% during the review period.
The rising rate of parasitic contaminations and the rising pervasiveness of immunological infections are emphatically adding to the market development.
Contagious diseases incorporate both foundational and shallow contaminations, including contaminations of the skin, eye, mouth, and vagina. Antifungal items with fungicidal movement are for the most part used to treat a wide cluster of illnesses, like competitor's foot, ringworm, and parasitic meningitis, brought about by contagious specialists.
Also, there are a few items accessible related with various courses of organization on the market for the treatment of contagious diseases, like oral and intravenous prescriptions, creams, splashes, shampoos, arrangements, pessaries, and infusions. Moreover, expanding dispatches of imaginative items is further fueling the development of the market. For example, in May 2022, Bayer AG (Germany) sent off a better than ever Canesten antifungal treatment arrangement in India. The product offering, which is accessible in powder and cream structures, has against parasitic properties that guide in the counteraction and treatment of skin contaminations. The antifungal cream gives alleviation from contamination, and the gentle steroid cream lessens the irritation because of disease.
Thus, the high accessibility of various courses of organization and the rising predominance of various sorts of contagious contaminations are encouraging market development.

Market Segmentation
The Antifungal Treatment Market is divided into drug classes, such as azoles, echinocandins, polyenes, allylamines, pyrimidines, and others.
Oral, topical, and parenteral are the categories into which the market is divided based on the mode of administration.
Dermatophytosis, aspergillosis, candidiasis, invasive candidiasis, vulvovaginal candidiasis, mouth/throat/esophageal candidiasis, and others are the segments of the market based on the indication.
The Antifungal Treatment Market is divided into categories based on pathogens, including zygomycetes, trichophyton, aspergillus, cryptococcus, and coccidioides immitis. Clinics for dermatology, hospitals & clinics, and other categories make up the end user market.
Regional Analysis
North America represented the biggest market portion of more than 40% in 2022 is attributable to different variables and one of them is expanding number of individuals with contagious contaminations. Also, market players are shaping methodologies to disseminate and sell antifungal medication in the US.
The Europe against contagious contamination market development is driven by significantly obtrusive parasitic diseases, which have been emphatically expanding since the last 10 years in the European nations. Also, patients with hematologic malignancies and hematopoietic cell relocate beneficiaries (HCT) are found to get obtrusive parasitic contaminations in the European populace.
The Asia-Pacific enemy of parasitic treatment market is the quickest developing region during the forecast time frame attributable to expanding contagious disease cases in Asian nations. In 2020, the Worldwide Activity for Parasitic Diseases (GAFFI) and Fudan College (Shanghai) assessed that 1,000,000 individuals experience the ill effects of obtrusive aspergillosis in China every year.
Major Players
Key Companies in the Antifungal Treatment Market includes Pfizer Inc (US), Johnson & Johnson Services, Inc (US), Bayer AG (Germany), Novartis AG (Switzerland), Abbott Laboraotories, Inc. (US), Merck KGaA (Germany), Gilead Sciences, Inc (US), Cipla, Inc. (India), Sanofi S.A. (France), and GlaxoSmithKline Plc (UK).

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING INCIDENTS OF FUNGAL INFECTIONS

4.2.2 INCREASING PREVALENCE OF IMMUNOLOGICAL DISEASES

4.2.3 AVAILABILITY OF A WIDE RANGE OF PRODUCTS

4.3 RESTRAINTS

4.3.1 SIDE-EFFECTS OF TREATMENT

4.4 OPPORTUNITIES

4.4.1 DEVELOPMENT OF NEW DRUGS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL ANTI-FUNGAL TREATMENT MARKET

5.3.1 IMPACT ON MAKET GROWTH

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON DIAGNOSTICS AND TESTING

5.3.4 CHANGES IN HEALTHCARE PRIORITIES

5.3.5 IMPACT ON CLINICAL TRIALS

6 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS

6.1 OVERVIEW

6.2 AZOLES

6.3 ECHINOCANDINS

6.4 POLYENES

6.5 ALLYLAMINES

6.6 PYRIMIDINES

6.7 OTHERS

7 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.1 OVERVIEW

7.2 ORAL

7.3 TOPICAL

7.4 PARENTERAL

8 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION

8.1 OVERVIEW

8.2 DERMATOPHYTOSIS

8.3 ASPERGILLOSIS

8.4 CANDIDIASIS.

8.5 INVASIVE CANDIDIASIS.

8.6 VULVOVAGINAL CANDIDIASIS

8.7 MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS

8.8 OTHERS

9 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS

9.1 OVERVIEW

9.2 CANDIDA

9.3 ASPERGILLUS

9.4 CRYPTOCOCCUS

9.5 COCCIDIOIDES IMMITIS.

9.6 ZYGOMYCETES

9.7 TRICHOPHYTON

9.8 OTHERS

10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL AND CLINICS

10.3 DERMATOLOGICAL CLINICS

10.4 OTHERS

11 GLOBAL ANTI-FUNGAL TREATMENT MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 UK

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 SWITZERLAND

11.3.7 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 INDIA

11.4.3 JAPAN

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 COMPETITIVE BENCHMARKING

12.3 MAJOR GROWTH STRATEGY IN THE ANTI-FUNGAL TREATMENT MARKET

12.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE ANTI-FUNGAL TREATMENT MARKET

12.5 KEY DEVELOPMENT ANALYSIS

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

12.6.2 ACQUISITION

12.6.3 AGREEMENT

12.6.4 PARTNERSHIP

12.6.5 EXPANSION

12.7 MAJOR PLAYERS FINANCIAL

12.7.1 SALES (USD BILLION), 2022

12.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD BILLION), 2022

13 COMPANY PROFILES

13.1 PFIZER INC

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 MERCK KGAA

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 GILEAD SCIENCES, INC

13.3.1 COMPANY OVERVIEWS

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 KEY STRATEGIES

13.4 BAYER AG

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 KEY STRATEGIES

13.5 CIPLA INC

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCTS OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 KEY STRATEGIES

13.6 NOVARTIS AG

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 SANOFI S.A.

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCTS OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 ABBOTT

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 KEY STRATEGIES

13.9 JOHNSON & JOHNSON SERVICES, INC

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 GLAXOSMITHKLINE PLC

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR AZOLES, BY REGION 2019–2032 (USD BILLION)

TABLE 5 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ECHINOCANDINS, BY REGION 2019–2032 (USD BILLION)

TABLE 6 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR POLYENES, BY REGION 2019–2032 (USD BILLION)

TABLE 7 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ALLYLAMINES, BY REGION 2019–2032 (USD BILLION)

TABLE 8 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PYRIMIDINES, BY REGION 2019–2032 (USD BILLION)

TABLE 9 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)

TABLE 10 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 11 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ORAL, BY REGION 2019–2032 (USD BILLION)

TABLE 12 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TOPICAL, BY REGION 2019–2032 (USD BILLION)

TABLE 13 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR PARENTERAL, BY REGION 2019–2032(USD BILLION)

TABLE 14 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032(USD BILLION)

TABLE 15 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOPHYTOSIS, BY REGION 2019–2032 (USD BILLION)

TABLE 16 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLOSIS, BY REGION 2019–2032 (USD BILLION)

TABLE 17 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)

TABLE 18 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR INVASIVE CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)

TABLE 19 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR VULVOVAGINAL CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)

TABLE 20 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR MOUTH/THROAT/ESOPHAGEAL CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)

TABLE 21 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)

TABLE 22 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY PATHOGENS, 2019–2032 (USD BILLION)

TABLE 23 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDA, BY REGION 2019–2032 (USD BILLION)

TABLE 24 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ASPERGILLUS, BY REGION 2019–2032 (USD BILLION)

TABLE 25 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CRYPTOCOCCUS, BY REGION 2019–2032 (USD BILLION)

TABLE 26 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR CANDIDIASIS, BY REGION 2019–2032 (USD BILLION)

TABLE 27 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR ZYGOMYCETES, BY REGION 2019–2032 (USD BILLION)

TABLE 28 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR TRICHOPHYTON, BY REGION 2019–2032 (USD BILLION)

TABLE 29 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)

TABLE 30 GLOBAL ANTIFUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 31 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR HOSPITALS AND CLINICS, BY REGION 2019–2032 (USD BILLION)

TABLE 32 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR DERMATOLOGICAL CLINICS, BY REGION 2019–2032(USD BILLION)

TABLE 33 GLOBAL ANTIFUNGAL TREATMENT MARKET, FOR OTHERS, BY REGION 2019–2032 (USD BILLION)

TABLE 34 GLOBAL: ANTI-FUNGAL TREATMENT MARKET, BY REGION, 2019–2032(USD BILLION)

TABLE 35 NUMBER OF DEATHS FROM FUNGAL INFECTIONS IN THE US DURING 2019–2021

TABLE 36 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032(USD BILLION)

TABLE 37 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 38 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 39 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 40 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 41 NORTH AMERICA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 42 US: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 43 US: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 44 US: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 45 US: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 46 US: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 47 CANADA: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 48 CANADA: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 49 CANADA: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 50 CANADA: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 51 CANADA: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 52 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032(USD BILLION)

TABLE 53 EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 54 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 55 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 56 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 57 EUROPE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 58 GERMANY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 59 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 60 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 61 GERMANY ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 62 GERMANY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 63 FRANCE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 64 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 65 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 66 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 67 FRANCE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 68 UK: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 69 UK: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 70 UK: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 71 UK: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 72 UK: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 73 ITALY: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 74 ITALY: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 75 ITALY: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 76 ITALY: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 77 ITALY: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 78 SPAIN: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 79 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 80 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 81 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 82 SPAIN: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 83 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 84 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 85 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 86 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 87 SWITZERLAND: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 88 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032(USD BILLION)

TABLE 89 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY ROUTE OF ADMINISTRATION, 2019–2032(USD BILLION)

TABLE 90 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY INDICATION, 2019–2032(USD BILLION)

TABLE 91 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY PATHOGEN, 2019–2032(USD BILLION)

TABLE 92 REST OF EUROPE: ANTI-FUNGAL TREATMENT MARKET BY END USER, 2019–2032(USD BILLION)

TABLE 93 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 94 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 95 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 96 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 97 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 98 ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 99 CHINA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 100 CHINA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 101 CHINA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 102 CHINA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 103 CHINA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 104 INDIA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 105 INDIA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 106 INDIA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 107 INDIA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 108 INDIA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 109 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 110 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 111 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 112 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 113 JAPAN ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 114 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 115 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 116 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 117 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 118 SOUTH KOREA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 119 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 120 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 121 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 122 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 123 AUSTRALIA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 124 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 125 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 126 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 127 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 128 REST OF ASIA-PACIFIC ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 129 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 130 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 131 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 132 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 133 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 134 REST OF THE WORLD ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 135 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 136 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 137 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 138 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 139 MIDDLE EAST ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 140 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 141 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 142 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 143 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 144 AFRICA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 145 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD BILLION)

TABLE 146 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD BILLION)

TABLE 147 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 148 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY PATHOGEN, 2019–2032 (USD BILLION)

TABLE 149 LATIN AMERICA ANTI-FUNGAL TREATMENT MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 150 MAJOR PLAYERS IN THE ANTI-FUNGAL TREATMENT MARKET

TABLE 151 MOST ACTIVE PLAYER IN THE ANTI-FUNGAL TREATMENT MARKET

TABLE 152 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 153 ACQUISITION

TABLE 154 AGREEMENT

TABLE 155 PARTNERSHIP

TABLE 156 EXPANSION

TABLE 157 PFIZER INC: PRODUCTS OFFERED

TABLE 158 PFIZER INC: KEY DEVELOPMENTS

TABLE 159 MERCK KGAA: PRODUCTS OFFERED

TABLE 160 GILEAD SCIENCES, INC: PRODUCTS OFFERED

TABLE 161 SBAYER AG: PRODUCTS OFFERED

TABLE 162 BAYER AG: KEY DEVELOPMENTS

TABLE 163 CIPLA INC: PRODUCTS OFFERED

TABLE 164 CIPLA INC: KEY DEVELOPMENTS

TABLE 165 NOVARTIS AG: PRODUCTS OFFERED

TABLE 166 SANOFI S.A.: PRODUCTS OFFERED

TABLE 167 ABBOTT: PRODUCTS OFFERED

TABLE 168 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED

TABLE 169 GLAXOSMITH KLINE PLC: PRODUCTS OFFERED

TABLE 170 GLAXOSMITH KLINE PLC: KEY DEVELOPMENTS